Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer May Be Regaining Appetite For Large M&A; Is Bristol On The Menu?

  • News

Executive Summary

Pfizer appears to be more open to large-scale mergers and acquisitions than it has been in recent years, comments by Vice Chairman David Shedlarz suggest

You may also be interested in...



Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist

The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm

Bristol Extends Interim CEO Cornelius’ Reign, But Acquisition Rumors Persist

The appointment of James Cornelius as Bristol-Myers Squibb's permanent CEO may be a de facto extension of his tenure as interim chief executive of the firm

Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table

Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS047580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By